These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32020164)

  • 1. Is Piperacillin-Tazobactam Really Comparable to Carbapenem for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?
    Wang JH; Lai CC
    Clin Infect Dis; 2020 Dec; 71(9):2539-2540. PubMed ID: 32020164
    [No Abstract]   [Full Text] [Related]  

  • 2. Which trial do we need? Piperacillin-tazobactam compared with a carbapenem for treatment of graft pyelonephritis caused by extended spectrum β-lactamase-producing Enterobacteriaceae.
    Gueneau R; Henry B
    Clin Microbiol Infect; 2023 Jul; 29(7):823-825. PubMed ID: 36958687
    [No Abstract]   [Full Text] [Related]  

  • 3. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
    PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?
    Sharara SL; Amoah J; Pana ZD; Simner PJ; Cosgrove SE; Tamma PD
    Clin Infect Dis; 2020 Nov; 71(8):e331-e337. PubMed ID: 31859352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
    Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
    Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
    Zhang W; Yan CY; Li SR; Fan TT; Cao SS; Cui B; Li MY; Fan BY; Ji B; Wang L; Cui F; Cui J; Wang L; Guan Y; Wang JW
    Front Cell Infect Microbiol; 2023; 13():1093842. PubMed ID: 37207190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
    Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
    Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
    Maillard A; Delory T; Bernier J; Villa A; Chaibi K; Escaut L; Contejean A; Bercot B; Robert J; El Alaoui F; Tankovic J; Poupet H; Cuzon G; Lafaurie M; Surgers L; Joseph A; Paccoud O; Molina JM; Bleibtreu A;
    Int J Antimicrob Agents; 2023 Jul; 62(1):106809. PubMed ID: 37028731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
    Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
    Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
    Tamma PD; Rodriguez-Bano J
    Clin Infect Dis; 2017 Apr; 64(7):972-980. PubMed ID: 28362938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
    Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
    Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing
    Abodakpi H; Chang KT; Gao S; Sánchez-Díaz AM; Cantón R; Tam VH
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V
    Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study.
    Al Muqati H; Al Turaiki A; Al Dhahri F; Al Enazi H; Althemery A
    J Infect Public Health; 2021 Mar; 14(3):306-310. PubMed ID: 33618274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin/tazobactam vs carbapenems for patients with bacterial infection: Protocol for a systematic review.
    Petersen MW; Perner A; Sjövall F; Jonsson AB; Steensen M; Andersen JS; Achiam MP; Frimodt-Møller N; Møller MH
    Acta Anaesthesiol Scand; 2019 Aug; 63(7):973-978. PubMed ID: 31020663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
    Sugimoto N; Yamagishi Y; Mikamo H
    J Infect Chemother; 2017 Jan; 23(1):65-67. PubMed ID: 27693013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of multi-drug resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from clinical specimens at Bugando Medical Centre, Tanzania to Piperacillin-Tazobactam.
    Petro D; Mushi MF; Moremi N; Iddi S; Mirambo M; Seni J; Mshana SE
    Tanzan J Health Res; 2014 Jan; 16(1):54-7. PubMed ID: 26867273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.